Assessment of the pharmaceutical market in Poland after accession to the European Union

European Journal of Health Economics

Volumn 8, Issue 4, 2007, Pages 347-357

  Willert, Patricia L ^a,b  

^a UNIVERSITY OF MUNICH   (Germany)

^b NONE   (Germany)

Author keywords

European Union; Fourth hurdle; Health care; Pharmaceutical market; Poland; Reimbursement

Indexed keywords

BUDGET; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DRUG CONTROL; DRUG COST; DRUG INDUSTRY; ECONOMIC DEVELOPMENT; EUROPEAN UNION; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HUMAN; INVESTMENT; PATENT; POLAND; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE PRICING; REIMBURSEMENT; REVIEW; SAFETY;

COST-BENEFIT ANALYSIS; DRUG APPROVAL; DRUG COSTS; DRUG INDUSTRY; EUROPEAN UNION; HEALTH POLICY; HISTORY, 20TH CENTURY; HUMANS; LEGISLATION, DRUG; PATENTS AS TOPIC; POLAND; REIMBURSEMENT MECHANISMS;

EID: 35748943169     PISSN: 16187598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10198-006-0032-3     Document Type: Review

References (29)

1. AOK Bundesverband., Die EU-Beitrittsländer: Republik Polen. In: http://www.aok-bv.de/politik/agenda/euerweiterung/index_01457.html (2004)
2. Girouard, N., Imai, Y.: The health care system in Poland - OECD Economics Department, Working Paper 257. In: OECD Economics Department. http://www.ideas.repec.org/p/oed/oecdec/257.html (2000)
3. Polish Ministry of Health.: http://www.mz.gov.pl (2005)
4. Kawiorska, D.: SHA-Based Health Accounts in 13 OECD Countries: Poland. OECD Health Technical Paper No. 10. In: http://www.oecd.org/dataoecd/9/23/ 33664254.pdf (2004)
5. Pawlowska, A.: Das polnische Gesundheitssystem. Aktuelle Probleme der Europäischen Gesundheitssysteme. In: http://www.wiwi.euv-frankfurt-o. de/%7Eeconpol/lehre/seminar_2004/Polnisches_Gesundheitssystem.pdf (2004)
6. World Health Organisation Regional Office for Europe.: European observatory on health care systems: health care systems in transition, Poland. In: http://www.euro.who.int/document/e67136.pdf (1999)
7. World Health Organisation Regional Office for Europe., Highlights on health in Poland, http://www.euro.who.int/document/E74338.pdf (2001)
8. Eichler, H.G.: Pharmacoeconomics and the "4th hurdle": drug reimbursement policies in Central and Eastern Europe. Int. J. Clin. Pharmacol. Ther. 41, 1-2 (2003)
9. Ministerstwo Zdrowia.: Polityka Lowkowa Panstwa 2004-2008 r, http://www.mz.gov.pl (2004)
10. Organisation for Economic Co-operation and Development OECD Health.: Data. In: http://www.oecd.org/document/30/0,2340, en_2649_33929_12968734_1_1_1_1,00. html (2004)
11. Chawla, M., Berman, P., Kawiorska, D.: Financing health services in Poland: new evidence on private expenditures. Health Econ. 7, 337-346 (1998)
12. Watson, N.: Poland's broken promises, Lancet 364, 235-238 (2004)
13. Stefan Batory Foundation.: Annual Report 2004. In:Stefan Batory Foundation, Warsaw http://www.batory.org/publications.html (2004)
14. World Health Organisation Regional Office for Europe.: Pharmaceutical country profile Poland. In: http://www.euro.who.int/pharmaceuticals/Topics/ Overview/20020415_1 (2004)
15. Business Portal for Poland.: Polish pharmaceutical market value, 2001-2003. In:The Polish Market.com http://www.pharmapoland.com/index.php?item=2 (2004)
16. Cylwik, A., Górzyñski, M., Markiewicz, M., Piêtka, K., Szczepañska, K.: The global-local development strategy of the pharmaceutical sector in Poland: the case of GSK Pharmaceuticals. CASE-Advisors, Warsaw (2003)
17. Epsicom Business Intelligence., World Pharmaceutical Market Poland. In: http://www.espicom.com/web.nsf/structure/TocsWPM02/$File/Poland.PDF (2003)
18. London School of Economics., Study on healthcare in individual countries, worldwide survey on pharmaceutical pricing and reimbursement structures: Poland, Health care, Pharmaceutical Pricing and Reimbursement. In: http://www.pharmacos.eudra.org/F3/g10/docs/tse/Poland.pdf (2004)
19. Krzyzanowska, A.: Personal communication. GlaxoSmithKline S.A., Warzawa (2004)
20. The Boston Consulting Group.: PhRMAproject on government interventions in pharmaceutical markets in OECD countries: overview of government interventions in OECD countries. In: Boston Consulting Group Publications (2004)
21. De Joncheere, K.: Pharmaceutical policies in Europe: selecting medicines for quality and affordable treatment. In: 3rd Baltic conference on Medicines, Tallinn (2004)
22. Orlewska, E., Mierzejewski, P.: Polish guidelines for conducting pharmaco-economic evaluations, Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw (2004)
23. PMR report: 2004 revealed new trends on the Polish pharma market, PMR Ltd, ul. Supniewskiego (2005)
24. Business Portal for Poland. Market news: terrifying results of NIK control on refunded drugs 2001-2003, The Polish Market.com http://www. pharmapoland.com/next.php?id=11677 (2004)
25. Business Portal for Poland. Market news: reimbursement committee liquidated. In: The Polish Market.com http://www.pharmapoland.com/next.php?id= 11684 (2004)
26. Business Portal for Poland. Ideas for improving health care-economist roundtable on healthcare reform in Poland, The Polish Market.com http://www.polishmarket.com/next.php?id=12129 (2004)
27. Neumann, P.J., Johannesson, M.: From principle to public policy: using cost-effectiveness analysis. Health Aff. (Millwood) 13, 206-214 (1994)
28. Paul, J.E., Trueman, P.: 'Fourth hurdle reviews', NICE, and database applications. Pharmacoepidemiol. Drug Saf. 10, 429-438 (2001)
29. Maynard, A., Bloor, K.: Dilemmas in regulation of the market for pharmaceuticals. Health Aff. (Millwood) 22, 31-41 (2003)